Results 191 to 200 of about 79,537 (233)

Poziotinib for uncommon ERBB mutations [PDF]

Nature Reviews Clinical Oncology, 2018
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

Molecular Cancer Therapeutics, 2004
Abstract The ErbB receptors are localized to the cell membrane where they are activated by ligand to trigger a network of signaling pathways. In some cancer cells, dysregulation of ErbB-mediated signaling confers a growth advantage, resulting in cellular transformation and increased metastatic potential.
openaire   +2 more sources

ErbB Targeted Drugs and Angiogenesis

Current Vascular Pharmacology, 2010
Members of the ErbB receptor tyrosine kinase family are central regulators of several normal as well as tumor cell functions. A number of therapeutic compounds such as small molecular weight tyrosine kinase inhibitors and monoclonal antibodies have been developed to inhibit ErbB signaling in cancer.
Erika, Iivanainen, Klaus, Elenius
openaire   +2 more sources

ErbB Receptors and Cancer

2017
The ErbB receptor family, also known as the EGF receptor family or type I receptor family, includes the epidermal growth factor (EGF) receptor (EGFR) or ErbB1/Her1, ErbB2/Her2, ErbB3/Her3, and ErbB4/Her4. Among all RTKs, EGFR was the first RTK identified and the first one linked to cancer. Thus, EGFR has also been the most intensively studied among all
openaire   +2 more sources

ErbB‐3 and ErbB‐4 Expression in the Mouse Olfactory System^a

Annals of the New York Academy of Sciences, 1998
ABSTRACT: The interplay between neuregulins and the ErbB receptor family has a pivotal role in the development of several tissues, including the nervous system, and is maintained in the adult olfactory system where extensive plasticity and neurogenesis are retained.
PERROTEAU, Isabelle, OBERTO M, IERACI A, BOVOLIN, Patrizia, FASOLO, Aldo   +4 more
openaire   +3 more sources

Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome

Lung Cancer, 2007
The expression of c-erbB receptors was immunohistochemically examined in paraffin embedded specimens from non-small-cell lung carcinomas. A total of 209 patients were enrolled [squamous-cell carcinomas (n=59), adenocarcinomas (n=130), large-cell carcinomas (n=15) and giant-cell carcinomas (n=5)].
Anastassios V, Koutsopoulos, Dimitris, Mavroudis, Konstantina I, Dambaki, John, Souglakos, Eleni G, Tzortzaki, John, Drositis, George S, Delides, Vassilis, Georgoulias, Efstathios N, Stathopoulos   +8 more
openaire   +2 more sources

ErbB family targeting.

Current opinion in investigational drugs (London, England : 2000), 2004
Drugs for specific molecular targets have generated a great deal of excitement for their potential in cancer treatment, particularly with respect to our molecular understanding of cancer in recent years. The clinical utility of antibodies and small molecule kinase inhibitors has been demonstrated.
Jennifer D, Black, Michael G, Brattain, Smitha A, Krishnamurthi, Dawn M, Dawson, James K, Willson   +4 more
openaire   +1 more source

ErbB family

British Journal of Pharmacology, 2006
S P H Alexander, A Mathie, J A Peters
openaire   +1 more source

Targeting ERBB Receptors in Cancer

2007
Tyrosine kinases are a large and diverse family of proteins found only in metazoans. The ERBB family, which encompasses subgroup I of the receptor tyrosine kinase (RTK) superfamily, has four members: epidermal growth factor receptor (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4.
openaire   +2 more sources

Antitumour immunity regulated by aberrant ERBB family signalling

Nature Reviews Cancer, 2021
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa   +2 more
exaly